Lördag 21 December | 17:45:33 Europe / Stockholm

Kalender

Tid*
2024-11-19 - Kvartalsrapport 2024-Q3
2024-08-29 - Kvartalsrapport 2024-Q2
2024-05-30 - Kvartalsrapport 2024-Q1
2024-04-25 - Extra Bolagsstämma 2024
2024-04-19 - X-dag ordinarie utdelning LYTIX 0.00 NOK
2024-04-18 - Årsstämma
2024-02-29 - Bokslutskommuniké 2023
2023-11-09 - Kvartalsrapport 2023-Q3
2023-08-31 - Kvartalsrapport 2023-Q2
2023-05-11 - Kvartalsrapport 2023-Q1
2023-04-19 - X-dag ordinarie utdelning LYTIX 0.00 NOK
2023-04-18 - Årsstämma
2023-02-16 - Bokslutskommuniké 2022
2022-11-17 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-12 - Kvartalsrapport 2022-Q1
2022-04-22 - X-dag ordinarie utdelning LYTIX 0.00 NOK
2022-04-21 - Årsstämma
2022-02-17 - Bokslutskommuniké 2021

Beskrivning

LandNorge
ListaEuronext Growth Oslo
SektorHälsovård
IndustriBioteknik
Lytix Biopharma är ett bioteknikbolag i kliniskt stadium som utvecklar nya cancerimmunterapier. Bolagets teknik bygger på forskning inom antimikrobiella peptider, ett försvar riktade mot patogener. Lytix Biopharmas huvudprodukt, LTX-315, är en onkolytisk peptid med syftet att personalisera immunterapi. Bolaget bedriver sin forskning och verksamhet i Oslo, Norge.
2022-05-03 13:07:47
Lytix Biopharma ("Lytix"),  is pleased to announce that it will host a Capital
Markets Day for investors, analysts and media on Wednesday, June 1, 2022.

The event will be open for physical attendance in Oslo, Norway, as well as a
live webcast. It is scheduled to start at 14.00 CET, and is expected to last
approximately two hours, including Q&A.

Speakers will be Ted White, CEO of Verrica Pharmaceuticals Inc. ("Verrica"),
Gary Goldenberg, CMO of Verrica, Aurelien Marabelle, visiting professor at
Stanford University and an internationally recognized expert on intratumoral
cancer treatment, and Øystein Rekdal, CEO of Lytix Biopharma.

Verrica has an exclusive worldwide license agreement with Lytix to develop and
commercialize its lead compound, LTX-315, for dermatologic oncology conditions,
and the first patient has been dosed in Verrica's Phase II study evaluating
LTX-315 for intratumoral treatment of basal cell carcinoma (skin cancer). At the
CMD the focus will be... See attached flyer.

Further details of the agenda and registration details will follow.